Moderna Shares Skyrocket on Promising Cancer Treatment Results

Moderna's stock price surged over 120% to $140.12 per share after the company announced promising results from a study on its experimental cancer treatment, intismeran.

The mRNA-based vaccine is being developed in partnership with Merck and is designed to be tailored to individual patients based on unique mutations within their tumors.

In the current study, patients who received the combination of intismeran and Keytruda, an immunotherapy drug made by Merck, lived longer without cancer returning or metastasizing than those who got Keytruda alone.